Amunix unveils next-generation immunooncologic cancer therapy platform

A novel immunotherapy with extended serum half-life in a prodrug delivery format holds promise for overcoming the limitations of current BiTE therapies to treat a broad range of malignancies. To download the full article please sign in.

Like Comment
Page of
Go to the profile of Amunix


Amunix is an industry leader in the discovery and development of long-acting protein- and peptide therapeutics. Founded in 2006, Amunix’ pipeline products are based on its proprietary XTEN® half-life extension, XDC drug-conjugate delivery and ProTIA pro-drug, bispecific T cell engager platform technologies. Located in Mountain View, CA, Amunix is progressing the development of its internal pipeline and also has ongoing collaborations with a number of established and emerging biopharma corporations harnessing these delivery technologies in a wide range of therapeutic areas, delivering improved pharmaceutical safety, efficacy and dosing.

No comments yet.